Evidence map›Paper›PMID 41254356›Full record

ArticleChembiochem : a European journal of chemical biology2025

Development of a Genetically Encoded and Potent PDE6D Inhibitor.

Atanasio Gómez-Mulas, Elisabeth Schaffner-Reckinger, Hanne Peeters, Rohan Chippalkatti, Arnela Dautbasic, Matthew James Smith, Shehab Ismail, Daniel Kwaku Abankwa

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Development of a Genetically Encoded and Potent PDE6D Inhibitor.Chembiochem : a European journal of chemical biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Atanasio Gómez-MulasCancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 2 place de l'Université, 4365, Esch-sur-Alzette, Luxembourg.ORCID https://orcid.org/0009-0002-9841-5580
Elisabeth Schaffner-ReckingerCancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 2 place de l'Université, 4365, Esch-sur-Alzette, Luxembourg.ORCID https://orcid.org/0000-0002-0321-3621
Hanne PeetersThe Mechanistic Molecular Biochemistry Group, Department of Chemistry, KU Leuven, Celestijnenlaan 200G, 3001, Heverlee, Belgium.ORCID https://orcid.org/0000-0001-7419-8812
Rohan ChippalkattiCancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 2 place de l'Université, 4365, Esch-sur-Alzette, Luxembourg.ORCID https://orcid.org/0000-0002-1419-6329
Arnela DautbasicCancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 2 place de l'Université, 4365, Esch-sur-Alzette, Luxembourg.ORCID https://orcid.org/0009-0004-2416-1228
Matthew James SmithInstitute for Research in Immunology and Cancer, Pavillon Marcelle-Coutu, Université de Montréal, 2950 Chemin de Polytechnique, Montréal, Québec, H3T 1J4, Canada.ORCID https://orcid.org/0000-0003-2896-9350
Shehab IsmailThe Mechanistic Molecular Biochemistry Group, Department of Chemistry, KU Leuven, Celestijnenlaan 200G, 3001, Heverlee, Belgium.ORCID https://orcid.org/0000-0002-4150-1077
Daniel Kwaku AbankwaCancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 2 place de l'Université, 4365, Esch-sur-Alzette, Luxembourg.ORCID https://orcid.org/0000-0003-2769-0745

Funding

FWO G042824NLuxembourg National Research Fund AFR/23/17112420/Bil_ABANKWA_SPREDCanUL2Luxembourg National Research Fund INTER/FWO/23/18086068 molGluRAS2
6 · The paper itself

Abstract

PDE6D is a trafficking chaperone of prenylated proteins, such as small GTPases. Several small molecule inhibitors have been developed against it, given that the oncogene K-Ras is one of the cargo proteins. Inhibitor development suffers from the fact that inhibitors against the hydrophobic pocket of PDE6D are typically poorly water-soluble. Herein, the development of genetically encoded inhibitors that are inspired by high-affinity natural cargo of PDE6D is described. The most potent inhibitor, SNAP-STI, encodes merely a farnesylated tetra-peptide, which efficiently blocks PDE6D binding of farnesylated cargo. Direct comparison with small molecule PDE6D inhibitors suggests its higher potency. It is shown that inhibition of K-Ras membrane anchorage and K-RasG12C-dependent MAPK signaling by SNAP-STI is weak, consistent with what is observed after PDE6D knockdown. The data therefore further support that PDE6D is not a suitable surrogate target for efficient inhibition of K-Ras membrane anchorage and MAPK-activity. Nonetheless, by exploiting contacts at the pocket entry, a generalizable strategy to design high-affinity PDE6D inhibitors is established, providing powerful tools for PDE6D biology and target validation.

Indexed as

Cyclic Nucleotide Phosphodiesterases, Type 6HumansCyclic Nucleotide Phosphodiesterases, Type 6cancerinhibitorsPDE6DRASRASopathy

Identifiers

PMID41254356
PMCPMC12703448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.